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1. Introduction
These guidelines for the clinical management and laboratory 
investigation of venous thrombo-embolism (VTE) in neonates 
and children reflect current best practice. Recommendations 
presented are in accordance with the more comprehensive 
evidence-based guidelines for paediatric antithrombotic therapy, 
including the American College of Chest Physicians (ACCP) 
guidelines, the United Kingdom paediatric stroke guidelines 
and the American Heart Association guidelines for paediatric 
stroke.1-6 Many of the recommendations are Grade 2C, indicating 
the lack of strong evidence (Table 1). The most current paediatric 
recommendations are extrapolated from adult trials; therefore, 
management should be individualised in consultation with 
a haematologist with appropriate consideration for the risk/
benefit ratio of each patient. Drug recommendations are based 
on Medicines Control Council registration at the time of 
publication.
2. Antithrombotic therapy in 
paediatric patients
The aim of primary anticoagulation is to prevent thrombus 
propagation and to achieve clot resolution. Antithrombotic 
therapy in paediatric patients cannot be extrapolated directly 
from adult recommendations. Features specific to the paediatric 
age group include:
•	 The aetiology of VTE: the presence of a central venous 
catheter (CVC) is the most important risk factor for the 
development of thrombosis in neonates and children. 
Additional documented risk factors include sepsis, perinatal 
hypoxia, dehydration, maternal diabetes and polycythaemia in 
neonates, and congenital heart disease, cancer, chemotherapy, 
protein-losing states, total parenteral nutrition (TPN) and 
trauma/surgery in children.
•	 The haemostatic system is a dynamic and evolving system 
that matures in late adolescence. This affects the frequency 
of VTEs in children and the response to antithrombotic 
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Table 1. Grading recommendation of the ACCP for anti-
thrombotic therapy
Grade Methodological quality of supporting evidence
1A Consistent evidence from randomised clinical trials 
(RCTs) without important limitation or exceptional 
strong evidence from observational studies
1B Evidence from RCTs with important limitations 
(inconsistent results, methodological flaws) or very 
strong evidence from observational studies
1C Evidence for at least one critical outcome from 
observational studies, case series or from RCTs with 
serious flaws
2A Consistent evidence from RCTs without important 
limitations or exceptional strong evidence from 
observational studies
2B Evidence from RCTs with important limitations 
(inconsistent results, methodological flaws or very 
strong evidence from observational studies)
2C Evidence for at least one critical outcome from 
observational studies, case series or from RCTs with 
serious flaws or indirect evidence
172 March 2012, Vol. 102, No. 3  SAMJ
therapies. VTE in the paediatric age group is rare compared 
with adults, with a peak incidence in the neonatal period and 
adolescence.
•	 Limited vascular access.
The management of neonates and children should also be 
considered separately, because they differ in terms of the 
aetiologies of VTE and the pharmacokinetics of antithrombotic 
therapies.
3. Specific indications for 
antithrombotic therapy
•	 Many of the recommendations are Grade 2C, indicating that most 
of the data are based on observational studies. 
•	 Before the initiation of antithrombotic therapy, baseline testing 
of partial thromboplastin time (PTT), prothrombin time (PT)/
international normalised ratio (INR) and platelet count should be 
performed.
•	 Intracranial bleeding should be excluded, especially in premature 
infants, by cranial ultrasound.
•	 The duration of antithrombotic therapy needs to be 
individualised according to the patient’s thrombo-embolic 
and bleeding risk; raised D-dimers >0.5 mg/l and residual 
thrombus after 3 - 6 months of antithrombotic therapy are 
considered to be risk factors for recurrent VTE.
3.1 Neonatal VTE
•	 CVC-related VTEs account for two-thirds of VTE.
•	 Immediate removal of the catheter, if possible, is suggested.
•	 The optimal duration of anticoagulation remains undefined, but 
short-term therapy with low molecular weight heparin (LMWH) 
or unfractionated heparin (UFH) for 10 - 14 days is suggested, 
with objective radiological monitoring (echocardiography or 
ultrasound) performed both during and after the completion of 
anticoagulant therapy.
•	 If there is evidence of a new or extending thrombus following 
completion of initial therapy, anticoagulation should be 
recommenced.
•	 Thrombolytic therapy for neonatal VTE is not recommended.
3.2 Neonatal renal vein thrombosis (RVT)
•	 It is suggested that anticoagulation with LMWH or UFH be given 
for 3 months for unilateral RVT. 
•	 In addition to anticoagulation, thrombolytic therapy is suggested 
for bilateral RVT with renal failure.
3.3 Neonatal cerebral sinovenous thrombosis (CSVT)
•	 Anticoagulation with LMWH or UFH is suggested for at least 
6 weeks and up to 3 months for neonatal CSVT if there is no 
significant haemorrhage. Neonates recanalise at a faster rate than 
older children and radiological assessment for recanalisation 
can be performed at 6 weeks. If recanalisation is complete, 
anticoagulation therapy can be stopped.
•	 Radiological monitoring of the thrombosis at 5 - 7 days is 
recommended for neonatal CSVT with significant haemorrhage. 
Anticoagulation is suggested if thrombus extension is noted.
3.4 Purpura fulminans
•	 For neonates with homozygous protein C or S deficiency, the 
administration of fresh frozen plasma (10 - 20 ml/kg) every 6 - 12 
hours is recommended. Replacement therapy is recommended 
following 6 - 8 weeks, to facilitate resolution of the clinical 
lesions.
•	 Long-term anticoagulation with LMWH or warfarin is suggested.
3.5 VTE in children
•	 Initial anticoagulation with LMWH or UFH is recommended for 
at least 5 - 10 days, followed by warfarin or LMWH.
•	 Maintenance warfarin therapy can be started on day 1 or 2 of 
heparin therapy.
•	 Routine use of thrombolytic therapy is not recommended, unless 
there is major vessel occlusion causing critical compromise of 
limbs or organs.
•	 Suggested duration of anticoagulation:
•	 CVC-related VTE: at least 3 months with objective radiological 
monitoring (echocardiography or ultrasound) performed both 
during and after the completion of anticoagulant therapy
•	 Idiopathic VTE: at least 6 months
•	 Recurrent idiopathic VTE: long-term anticoagulation, possibly 
life-long
•	 Secondary VTE: until the risk factor (e.g. nephrotic syndrome or 
L-asparaginase chemotherapy) has resolved for at least 3 months.
3.6 CSVT in children
•	 Anticoagulation with LMWH or UFH for at least 5 - 10 days, 
followed by warfarin or LMWH is suggested for a minimum of 
3 months up to 6 months for CSVT in children if there is no 
significant haemorrhage.
•	 Radiological assessment for recanalisation can be performed at 3 
months. If recanalisation is complete, anticoagulation therapy can 
be stopped.
•	 Radiological monitoring of the thrombosis at 5 - 7 days is 
recommended for CSVT with significant haemorrhage; 
anticoagulation is suggested if thrombus extension is noted.
3.7 VTE associated with cancer and chemotherapy
•	 Routine antithrombotic prophylaxis is not recommended in 
paediatric patients with cancer due to the lack of evidence and the 
potential for increased bleeding.
3.8 Children with congenital heart defects post surgery 
•	 Intra- and/or postoperative therapy with UFH is suggested, 
followed by either aspirin (1 - 5 mg/kg/dose) or anticoagulation 
with LMWH or warfarin.
4. Antithrombotic drugs 
Antithrombotic drugs available for the management of VTE in the 
paediatric population include:
•	 LMWH
•	 UFH
•	 Vitamin K antagonists.
The guidelines below pertain to the use of LMWH (enoxaparin), 
UFH and warfarin.
4.1 LMWH (enoxaparin) 
LMWH offers definite advantages over UFH because of its superior 
bioavailability, longer half-life, dose-dependent clearance (resulting 
in a more predictable anticoagulant response), subcutaneous 
administration and minimal monitoring requirements. The use of 
LMWH should be avoided in renal insufficiency.
4.1.1 LMWH dose
The recommended doses for enoxaparin are as follows:
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Treatment dose:
•	 Administer enoxaparin at 1.5 mg/kg/dose subcutaneously (SC) per 
12 hours for neonates aged <2 months and <5 kg*.
•	 Administer enoxaparin at 1 mg/kg/dose SC per 12 hours for 
children aged 2 months - 16 years.
Prophylactic dose: 
•	 Administer enoxaparin at 0.75 mg/kg/dose SC per 12 hours for 
neonates aged <2 months.
•	 Administer enoxaparin at 0.5 mg/kg/dose SC per 12 hours for 
children aged 2 months - 16 years.
Available enoxaparin preparations often need to be diluted with 
sterile water to a concentration of 20 mg/ml to administer the small 
doses required. The preparation must be refrigerated after opening. 
4.1.2 Monitoring of therapy
•	 Avoid other antiplatelet drugs, intramuscular (IM) injections and 
arterial punctures during anticoagulation.
•	 Monitoring of LMWH is recommended in children, especially in 
neonates. In sick preterm neonates, the initiation dose of 2.0 mg/kg/
dose SC per 12 hours may be insufficient to achieve a therapeutic 
level. Close monitoring is advised in the initial treatment phase to 
avoid delays in achieving adequate anticoagulation. 
•	 Anticoagulant activity is measured using an anti-Xa activity assay.
•	 Anti-Xa monitoring should be performed in consultation with 
a haematologist. Testing is currently available at the Charlotte 
Maxeke Johannesburg Academic Hospital Coagulation Laboratory 
(+27 (0)11 489 8471/8534); the Red Cross Children’s Hospital 
Haematology Laboratory, Western Cape (+27 (0)21 658 5203/5204) 
as well as most private laboratories.
•	 A 5 ml citrate tube (or 2 x 1 ml paediatric citrate tubes) is required 
for the assay. Avoid sampling blood from indwelling lines. Samples 
must reach the reference laboratory (or local laboratory for 
shipping) within 1 hour. 
•	 Samples must be drawn 3 - 4 hours after the last LMWH subcutaneous 
injection and repeated until a therapeutic anti-Xa level is achieved.
•	 Once therapeutic levels are achieved, continued regular monitoring 
and dose adjustments for changes with growth are recommended. 
Target anti-Xa levels:
•	 Prophylaxis target: 0.2 - 0.4 anti-Xa U/ml
•	 Therapeutic target: 0.5 - 1.0 anti-Xa U/ml. 
Dose adjustments should be performed according to the nomogram 
in Table 2. If an inadequate response is achieved, the following should 
be considered:
*Neonates need a higher dose per body weight compared with older children because of their 
larger volume of distribution, accelerated drug clearance and lower plasma antithrombin levels. A 
higher initiation dose of enoxaparin at 1.7 mg/kg/dose SC per 12 hours for term neonates and 2.0 
mg/kg/dose SC per 12 hours for preterm neonates aged <28 weeks may be required to achieve a 
therapeutic anti-Xa level.
Low anti-Xa level:
•	 Timing of specimen draw
•	 Heparin resistance secondary to antithrombin deficiency, e.g. 
neonates, sepsis, consumption due to large thrombus
•	 Dilution and administration of LMWH 
•	 Dose of LMWH omitted
•	 Weight gain.
High anti-Xa level:
•	 Heparinised syringe
•	 Weight loss
•	 Renal dysfunction.
4.1.3 Management of bleeding
•	 LMWH (plasma half-life of 3 - 6 hours) should be discontinued, as 
well as any other agents that may contribute to bleeding .
•	 Measurement of anti-Xa levels may be indicated.
•	 One intravenous dose (IV) of protamine sulphate can neutralise 
about 75% of the anti-Xa activity.
•	 1 mg of protamine sulphate IV should be administered per 1 mg 
(equivalent to 100 anti-Xa units) of enoxaparin given in the last 
dose over 10 minutes.
•	 If the patient continues to bleed, a repeat dose of 0.5 mg protamine 
sulphate IV per 1 mg of enoxaparin, up to a maximum of 3 doses, 
can be administered. 
4.2 UFH
UFH may be preferentially used in children and neonates who are at 
risk of bleeding, have poor renal function or require surgery, in view 
of the short half-life, minimal renal excretion and rapid reversal by 
protamine sulphate.
4.2.1 UFH dose
The recommended doses for UFH are as follows:
Treatment dose:
•	 Administer a bolus of 25 - 50 U/kg IV over 10 minutes and an 
initial maintenance dose of 15 U/kg/h IV as a continuous infusion 
for preterm neonates.
•	 Administer a bolus of 75 - 100 U/kg IV over 10 minutes and an 
initial maintenance dose of 28 U/kg/h IV as a continuous infusion 
for term neonates.
•	 Administer a bolus of 75 - 100 U/kg IV over 10 minutes and an 
initial maintenance dose of 20 U/kg/h IV as a continuous infusion 
for children. 
•	 Neonates need a higher maintenance dose per body weight 
compared with older children. 
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Table 2. Nomogram for adjusting enoxaparin therapeutic dose 
Anti-Xa level at peak Dose change Repeat anti-Xa level
<0.35 U/ml Increase by 25% 4 hours post next dose
0.35 - 0.49 U/ml Increase by 10% 4 hours post next dose
0.5 - 1.0 U/ml No change Monitor again in 2 weeks
1.1 - 1.5 U/ml Decrease by 20% 4 hours post next dose
1.6 - 2.0 U/ml Decrease by 30% 4 hours post next dose
>2.0 U/ml Hold further doses until anti-Xa measured 12-hourly is <0.5 U/ml
Recommence enoxaparin at 40% less than previous dose
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Prophylactic dose: 
•	 Administer UFH at 10 U/kg/h IV as a continuous infusion.
4.2.2 Monitoring of therapy
•	 Avoid other antiplatelet drugs, IM injections and arterial punctures 
during anticoagulation.
•	 The patient’s platelet count should be monitored on initiation 
of UFH and 7 days later while on therapy to assess for heparin-
induced thrombocytopenia (HIT). If the patient has been exposed 
to UFH in the last 100 days, a repeat platelet count is indicated 
within 24 hours of starting UFH. The risk of HIT is greatest after 
5 - 10 days of UFH therapy, but still rare in children. HIT should be 
considered when all other causes of thrombocytopenia have been 
ruled out. UFH should be stopped and other antithrombotic drugs 
should be started, e.g. Fondaparinux 0.1mg/kg SC daily.
•	 Anticoagulant activity is measured using a PTT test (or anti-Xa 
heparin assay). 
•	 A 5 ml citrate tube or 1 ml paediatric citrate tube is required for the 
assay. Avoid sampling blood from indwelling lines. 
Target levels:
•	 PTT: 60 - 85 seconds or 2 - 3 times the baseline value (if normal 
for age).
The PTT should be monitored 4 hours post bolus injection and the 
continuous IV dose adjusted according to the result (Table 3). 
4.2.3 Management of bleeding
•	 Bleeding can usually be controlled by stopping the infusion 
(plasma half-life of 25 minutes in neonates and 1 - 2 hours in 
children).
•	 If bleeding is life-threatening, immediate reversal of UFH activity 
can be achieved by administration of protamine sulphate (Table 4). 
•	 Administer protamine sulphate IV over 10 minutes at a 
concentration of 10 mg/ml. Rapid infusion can cause hypotension. 
•	 Following IV administration, neutralisation occurs within 5 
minutes.
•	 The maximum dose of protamine sulphate that can be administered 
is 50 mg.
4.3 Warfarin
Warfarin is not recommended in neonates. Warfarin administration 
in children is complicated by the need for frequent monitoring and 
dose adjustments due to diet interactions (low vitamin K in breast 
milk or high vitamin K in TPN and formula), intercurrent illness 
and drugs metabolised by cytochrome P450 enzymes. Warfarin 
is teratogenic and adolescent females should receive appropriate 
counselling.
4.3.1 Warfarin dose
The recommended dose for warfarin is as follows:
Treatment dose:
•	 Warfarin should always be preceded by heparin therapy.
•	 Initiate warfarin at a dose of 0.2 mg/kg to a maximum of 10 mg on 
day 1 or 2 of heparin therapy; if the patient has liver dysfunction 
or has had a Fontan procedure start at 0.1 mg/kg.
•	 Doses can be adjusted by small increments of 0.5 mg/dose (Table 5).
4.3.2 Monitoring of therapy
•	 Avoid other antiplatelet drugs, IM injections and arterial punctures 
during anticoagulation.
•	 Anticoagulant activity is monitored using an INR test.
•	 A 5 ml citrate tube or 1 ml paediatric citrate tube is required for 
the assay, with avoidance of sampling blood from indwelling lines 
•	 The INR should be monitored initially after 3 - 5 days and then 
daily until a therapeutic range is achieved; repeat INR is indicated 
5 - 7 days later.
•	 Heparin is not discontinued until the INR is therapeutic for 2 
consecutive days.
•	 Once stable, the INR should be monitored a minimum of once per 
month; most children require monitoring every 2 weeks.
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Table 3. Nomogram for adjusting UFH dose*
PTT (seconds) Bolus (U/kg) Hold infusion (minutes) Dose change             Repeat PTT (hours)
<50 50 0 Increase by 20%           4 
50 - 59 0 0 Increase by 10%          4 
60 - 85 0 0 No change 24
86 - 95 0 0 Decrease by 10%           4 
96 - 120 0 30 Decrease by 10%           4 
>120 0 60 Decrease by 15% 4
* The sensitivity of the PTT towards UFH depends on the reagent used.
Table 4. Nomogram for protamine sulphate* 
Time since last heparin dose  
(minutes)
Protamine sulphate dose per  
100 U heparin received (mg)
<30 1.0
30 - 60 0.5 - 0.75
60 - 120 0.375 - 0.5
>120 0.25 - 0.375
* Dosing is based on heparin dose received in the last 2 hours.
Table 5. Nomogram for adjusting warfarin dose
INR Dose change 
1.1 - 1.4 Increase by 20%
1.5 - 1.9 Increase by 10%
2.0 - 3.0 No change
3.1 - 3.5 Decrease by 20%
>3.5 Hold until INR <3.5
Recommence at 20% less than 
previous dose
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•	 Fluctuations of the INR outside the desired target range should be 
investigated.
Target levels:
•	 The target INR is 3.0 (range 2.5 - 3.5) for patients with valvular 
heart disease, antiphospholipid syndrome and warfarin failure. 
•	 The target INR is 2.5 (range 2.0 - 3.0) for other indications.
4.3.3 Management of bleeding
•	 Bleeding associated with warfarin therapy can be severe because of 
its long plasma half-life of 40 hours.
•	 If bleeding is significant, warfarin activity can be reversed 
immediately  by administration of fresh frozen plasma (10 - 20 
ml/kg IV) or vitamin K (0.5 - 1 mg) per os (PO) or slow IV. 
4.4 Systemic thrombolytic therapy
Thrombolytic therapy is not recommended in neonates. It is 
contraindicated if there is active bleeding, general surgery in the 
previous 10 days or neurosurgery in the previous 3 weeks. Tissue 
plasminogen activator (t-PA) is the preferred drug in children. 
4.4.1 t-PA dose
The recommended dose for t-PA is as follows:
Treatment dose:
•	 Start infusion at a rate of 0.5 mg/kg/h IV for 6 hours.
•	 Start heparin without a bolus at 20 U/kg/h IV during the t-PA 
infusion.
•	 Re-evaluate clinically and radiographically after 6 hours of t-PA 
infusion; if there is no response, a repeat t-PA infusion can be 
considered.
4.4.2 Monitoring of therapy
•	 Avoid other antiplatelet drugs, IM injections and arterial punctures 
during anticoagulation.
•	 Monitor full blood count (FBC), PT, PTT, fibrinogen and D-dimer 
levels 4 - 6 hourly.
•	 Adjust the continuous IV heparin dose according to the PTT result 
(Table 3).
Target levels:
•	 Fibrinogen >1.0 g/l 
•	 Platelets >100 x 109/l, and
•	 PTT 60 - 85 seconds or 2 - 3 times the baseline value
4.4.3 Management of bleeding
•	 Mild bleeding from a puncture site can be treated supportively and 
with local pressure. 
•	 If bleeding is significant, stop the t-PA infusion and administer 
cryoprecipitate at 1 U/5 kg and other blood products as indicated. 
•	 Protamine sulphate may be required to reverse the UFH activity 
(Table 4).
5. Thrombophilia testing 
VTE is often a multifactorial disease, and acquired risk factors in sick 
children often play a more important role than inherited risk factors.
5.1 Recommended investigations 
•	 Recommended first-line thrombophilia tests include conditions 
that are most prevalent in children (Table 6).
•	 Results must be interpreted in conjunction with age-adjusted 
reference ranges; abnormal results should be confirmed with 
repeat testing.
•	 The results of thrombophilia testing rarely influence early 
management decisions. 
•	 Testing is best done after 6 months of age, in the non-acute setting, 
and at least 2 weeks after discontinuation of anticoagulation 
therapy, because the results are altered by the acute event and by 
anticoagulant therapy.
•	 Exceptions include antithrombin levels (in the setting of heparin 
resistance), antiphospholipid antibodies (in the setting of maternal 
antiphospholipid syndrome), protein C and protein S in neonates 
presenting with purpura fulminans, and polymersase chain 
reaction (PCR) testing for Factor V Leiden and the prothrombin 
gene mutations.
5.2 Thrombophilia testing
•	 Thrombophilia testing should be strongly considered in adolescents 
with spontaneous VTE; this group has the highest prevalence of 
inherited thrombophilia.
•	 Thrombophilia testing for protein C, protein S and antithrombin 
should be strongly considered in neonates presenting with purpura 
fulminans, ischaemic skin lesions or extensive thrombosis.
•	 Thrombophilia testing should be considered in neonates and 
children with non-catheter-related VTE.
•	 Thrombophilia testing is not recommended with catheter-related 
VTE, but can be considered in neonates and children with 
recurrent catheter-related VTEs.
•	 Concomitant screening of both parents, with appropriate 
counselling, is recommended.
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Table 6. Recommended first-line thrombophilia tests in 
children
Thrombophilia Laboratory test 
Factor V Leiden 
mutation in 
caucasians
PCR or screening with a clotting assay 
(activated protein C resistance)
Prothrombin 
20210 mutation 
PCR
Antithrombin 
deficiency 
Chromogenic assay
Protein C 
deficiency 
Chromogenic assay 
Protein S 
deficiency
Functional clotting assay 
Lupus 
anticoagulant 
Clotting assays such as dilute partial 
thromboplastin time (dPTT), dilute Russell’s 
viper  venom time (dRVVT) and enzyme-
linked immunosorbent assay (ELISA) for 
anticardiolipin antibodies; positive results 
confirmed 12 weeks apart
